COMPANY RESEARCHEverest Medicines Ltd.
Everest Medicines is a Hong Kong-listed biopharmaceutical company engaged in developing, manufacturing and commercializing innovative medicines. The company works with internally developed capabilities and external partnerships to bring therapies to patients, with activities spanning several disease areas. Its portfolio and development strategy have included immunology, infectious diseases, renal conditions and other therapeutic needs. The official company website identifies its Hong Kong listing and provides investor disclosures alongside business information. Its work connects therapeutic development with manufacturing capabilities and commercial partnerships.
Company at a glance
Corporate information
- Company entity
- Everest Medicines
- Headquarters / principal office
- Hongkou District, Shanghai, China
Sources (1)
- Corporate headquarters disclosureUndated; checked 2026-11-04
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly traded (HKEX: 1952); public-market transactions tracked separately
Sources (1)
- Corporate ownership / financing disclosureChecked 2026-11-04; source publication date retained where stated
- Official corporate reference
- https://everestmedicines.com/product-science/pipeline-and-major-products
Sources (1)
- Everest Medicines — primary program / ownership disclosureUndated unless stated in source; checked 2026-11-04
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Everest Medicines is a Hong Kong-listed biopharmaceutical company engaged in developing, manufacturing and commercializing innovative medicines. The company works with internally developed capabilities and external partnerships to bring therapies to patients, with activities spanning several disease areas. Its portfolio and development strategy have included immunology, infectious diseases, renal conditions and other therapeutic needs. The official company website identifies its Hong Kong listing and provides investor disclosures alongside business information. Its work connects therapeutic development with manufacturing capabilities and commercial partnerships.
HKEX: 01952
mRNA therapeutics · drug development and commercialization
autoimmune disease · ophthalmology · cardiovascular and kidney disease · oncology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
EVM18 delivers CD19 CAR mRNA in targeted LNPs. Everest’s 2026 interim results report IIT initiation in autoimmune disease and global IND preparation. EVM14 and EVM16 are cancer vaccines, not its in vivo CAR-T lead.
Business, technology & evidence
- Everest Medicines is a Hong Kong-listed biopharmaceutical company engaged in developing, manufacturing and commercializing innovative medicines. The company works with internally developed capabilities and external partnerships to bring therapies to patients, with activities spanning several disease areas. Its portfolio and development strategy have included immunology, infectious diseases, renal conditions and other therapeutic needs. The official company website identifies its Hong Kong listing and provides investor disclosures alongside business information. Its work connects therapeutic development with manufacturing capabilities and commercial partnerships.
- SecuritiesHKEX: 01952
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| EVM18 | CD19 · See program source; distinguish indications | Exploratory human study / IIT | Human research disclosed or registered; efficacy is not established. |
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Unverified financing, founding dates, and clinical status are not inferred. Acquisitions/options are not financing rounds.
- Everest Medicines — primary program / ownership disclosure ↗Everest Medicines · Undated unless stated in source; checked 2026-11-04
- Everest Medicines — supporting primary disclosure ↗Everest Medicines · Undated unless stated in source; checked 2026-11-04
- Official issuer and R&D disclosure · Everest Medicines Ltd. ↗Everest Medicines Ltd. ·
- Official issuer and R&D disclosure · Everest Medicines Ltd. ↗Everest Medicines Ltd. ·
- Official issuer and R&D disclosure · Everest Medicines Ltd. ↗Everest Medicines Ltd. ·
- Corporate headquarters disclosure ↗everest · Undated; checked 2026-11-04
- Corporate ownership / financing disclosure ↗Everest Medicines · Checked 2026-11-04; source publication date retained where stated
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.